Search

Displaying results 2021 - 2030 of 4212 in total
  1. Drug

    Asenapine

    go.drugbank.com/drugs/DB06216
    ApprovedInvestigational

    Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with

  2. Drug

    Sulpiride

    go.drugbank.com/drugs/DB00391
    ApprovedWithdrawn

    [A229683] Sulpiride is not approved by the FDA, Health Canada, or the EMA; though it is approved in individual European countries.[L24679]

  3. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    [L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.

  4. Drug

    Fenbufen

    go.drugbank.com/drugs/DB08981
    Approved

    Fenbufen acts by preventing cyclooxygenase from producing prostaglandins which can cause inflammation.

  5. Drug

    Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10801
    ApprovedInvestigational

    Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria

  6. Drug

    Trichloroacetate

    go.drugbank.com/drugs/DB11152
    ApprovedInvestigational

    Trichloroacetate, or trichloroacetic acid, is a strong acid prepared by the reaction of chlorine with acetic acid in the presence of a suitable catalyst.

  7. Drug

    Formaldehyde

    go.drugbank.com/drugs/DB03843
    ApprovedVet approved

    A highly reactive aldehyde gas formed by oxidation or incomplete combustion of hydrocarbons.

  8. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    [L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin. … [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia

  9. Drug

    Sugemalimab

    go.drugbank.com/drugs/DB16641
    ApprovedInvestigational

    [L32868, L32873, L53333] The antibody is produced in Chinese hamster ovary cells by recombinant DNA technology. … Sugemalimab is a fully human, full-length anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (of the IgG4 isotype) discovered by CStone Pharmaceuticals.

  10. Drug

    NRP409

    go.drugbank.com/drugs/DB05235
    Experimental

    NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.